AC-150B

AC-150B is an ophthalmic drug formulation evaluated for the treatment of allergic conjunctivitis. It was studied as a 0.005% solution in clinical trials comparing its efficacy and safety to vehicle (placebo) and other components, such as AC-150A and combination formulations. The primary indication is the prevention or reduction of signs and symptoms associated with allergic conjunctivitis, specifically ocular itching following allergen challenge. The mechanism of action has not been explicitly detailed in available sources, but based on its use in allergic conjunctivitis models, it likely acts as an anti-allergic or anti-inflammatory agent targeting pathways involved in ocular allergy responses[1][2][6]. The developer listed for these studies is Aciex Therapeutics.